News
-
HIV Study Named 2011 Breakthrough Of The Year By Science
12/28/2011
The journal Science has chosen the HPTN 052 clinical trial, an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year.
-
Boehringer Ingelheim Completes Patient Entry For Phase III Trial Programme In Hepatitis C
12/22/2011
Boehringer Ingelheim recently announced that the final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335, its investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).
-
Janssen Biotech, Inc. Announces Collaborative Development And Worldwide License Agreement For Investigational Anti-Cancer Drug, PCI-32765
12/14/2011
Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced recently that it has executed an agreement with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.
-
Roche NimbleGen And BGI Develop Advanced MHC Region Capture Technology For Human Disease And Biomedical Research
11/30/2011
Roche NimbleGen, Inc. and BGI, the world’s largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen SeqCap EZ Choice Library, a revolutionary process for the enrichment of the MHC region.
-
Generex Subsidiary Antigen Express To Present AE37 Cancer Vaccine Phase 2 Clinical Data At 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11/23/2011
Generex Biotechnology Corporation (OTCBB: GNBT.OB) (www.generex.com) announced today that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will present new Phase 2 clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on December 7, 2011.
-
GE Healthcare Set To Revolutionize Imaging Of Live Cells With Launch Of Super-Resolution Imaging System
11/2/2011
Applied Precision Inc., a GE Healthcare company, recently announced the launch of DeltaVision OMX Blaze, a research microscopy system designed to reach the next level in the evolution of super-resolution imaging by employing a proprietary, ultra-fast, illumination module and the latest advanced high-speed camera technologies.
-
Phase II Study Showed Ocrelizumab Maintained Significant Reduction In Disease Activity For Multiple Sclerosis Patients For Almost Two Years
10/19/2011
Genentech, a member of the Roche Group, recently announced 96-week results1 from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form2 of the disease.
-
Novartis Drug Gilenya (Fingolimod) Has More Than 20,000 Patient-Years Of Exposure And Shows Up To 71% Reduction In Annualized Relapse Rates In MS Patients With Highly Active Disease
10/18/2011
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.
-
Leading Genomic Service And Technology Providers Help Raise Over $120k For Pediatric Genetics Research
10/7/2011
EA a leading provider of genomic services for clinical trials and research will once again host its “Leave Your Fingerprint on the Cure” campaign at the upcoming 12th International Congress of Human Genetics / American Society of Human Genetics 61st Annual Meeting http:/www.ichg2011.org This event is scheduled for October 12, 2011, in conjunction with the ICHG/ASHG 2011 Meeting in Montreal at the Palais des Congres de Montreal.
-
FDA Approves Remicade To Treat Ulcerative Colitis In Children 6 Years And Older
9/30/2011
The U.S. Food and Drug Administration recently approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children 6 years and older who have had inadequate response to conventional therapy.
This website uses cookies to ensure you get the best experience on our website. Learn more